Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD?
- PMID: 24535419
- DOI: 10.1038/nrneph.2014.20
Chronic kidney disease: empagliflozin-one step closer to glycaemic control in patients with type II diabetes and CKD?
Comment on
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. Lancet Diabetes Endocrinol. 2014. PMID: 24795251 Clinical Trial.
References
-
- Lancet Diabetes Endocrinol. 2014 May;2(5):369-84 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
